Related Experiment Video
Updated: May 12, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Resistant hypertension and target organ damage
Maria Lorenza Muiesan1, Massimo Salvetti, Damiano Rizzoni
1Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. muiesan@med.unibs.it
Insights
Resistant hypertension (RH) significantly increases cardiovascular risks and target organ damage (TOD). Effective treatments can control blood pressure and potentially reverse TOD, improving patient outcomes.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Cardiovascular (CV) complications like myocardial infarction, heart failure, stroke, and renal failure correlate with blood pressure (BP) elevation duration and severity.
- Resistant hypertension (RH) presents a heightened risk for CV complications and target organ damage (TOD).
- The interplay between CV disease and TOD is bidirectional, with elevated BP in RH causing CV alterations and TOD exacerbating hypertension control difficulties.
Purpose of the Study:
- To explore the link between resistant hypertension, cardiovascular complications, and target organ damage.
- To understand the bidirectional relationship between cardiovascular disease and target organ damage in resistant hypertension.
- To review therapeutic strategies for managing resistant hypertension and its associated target organ damage.
Main Methods:
- Literature review of studies investigating resistant hypertension, cardiovascular complications, and target organ damage.
- Analysis of the relationship between elevated blood pressure, structural/functional cardiovascular alterations, and target organ damage.
- Examination of comorbidities associated with resistant hypertension, such as obesity, sleep apnea, diabetes, metabolic syndrome, and hyperaldosteronism.
Main Results:
- Resistant hypertension is linked to increased prevalence of target organ damage and higher cardiovascular complication rates.
- Conditions like obesity, diabetes, and hyperaldosteronism, often co-occurring with RH, involve humoral/hormonal factors contributing to TOD.
- Elevated BP in RH can lead to left ventricular hypertrophy, aortic stiffness, atherosclerotic plaques, microvascular disease, and renal dysfunction.
Conclusions:
- Optimal therapeutic strategies, encompassing pharmacological and invasive methods, are crucial for managing resistant hypertension.
- Achieving adequate blood pressure control can induce regression of target organ damage.
- Effective management of resistant hypertension and associated target organ damage holds the potential to improve patient prognosis.
Abstract:
Cardiovascular (CV) complications such as myocardial infarction, heart failure, stroke and renal failure are related to both the degree and the duration of blood pressure (BP) increase. Resistant hypertension (RH) is associated with a higher risk of CV complications and a higher prevalence of target organ damage (TOD). The relationship between CV disease and TOD can be bidirectional. Elevated BP in RH may cause CV structural and functional alterations, and the development or persistence of left ventricular hypertrophy, aortic stiffness, atherosclerotic plaques, microvascular disease and renal dysfunction, may render hypertension more difficult to control. Specifically, RH is related to several conditions, including obesity, sleep apnea, diabetes, metabolic syndrome and hyperaldosteronism, characterized by an overexpression of humoral and hormonal factors that are involved in the development and maintenance of TOD. Optimal therapeutic strategies, including pharmacological treatment and innovative invasive methodologies, have been shown to achieve adequate BP control and induce the regression of TOD, thereby potentially improving patient prognosis.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension and Regulation of Blood Pressure
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

